

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the applications:

**Listing of Claims:**

1. (Previously presented) A method for activating at least one vascular endothelial growth factor selected from the group consisting of purified VEGF-C and purified VEGF-D, comprising treating said at least one vascular endothelial growth factor with a serine protease.

2. (Previously presented) The method according to claim 1, wherein the serine protease is plasmin.

3. (Previously presented) The method according to claim 1, wherein said at least one vascular endothelial growth factor is in an unprocessed form or a partially processed form.

4. (Previously presented) The method according to claim 1, wherein said vascular endothelial growth factor is VEGF-D.

5. (Previously presented) The method according to claim 1, wherein said vascular endothelial growth factor is VEGF-C.

6-14. (Canceled)

15. (Withdrawn) A method of treatment of a disorder selected from the group consisting of coronary artery disease, lymphedema, restenosis and stenosis comprising administering an effective amount of the pharmaceutical composition comprising an effective amount of a serine protease and a pharmaceutically acceptable excipient to a patient in need thereof.

16-17. (Canceled)

18. (Previously presented) The method according to claim 2, wherein the plasmin is purified.

19. (Previously presented) A method for activating at least one vascular endothelial growth factor selected from the group consisting of VEGF-C and VEGF-D, comprising treating said at least one vascular endothelial growth factor with a purified serine protease.

20. (Previously presented) The method according to claim 19, wherein said at least one vascular endothelial growth factor is in an unprocessed form or a partially processed form.

21. (Previously presented) The method according to claim 19, wherein said vascular endothelial growth factor is VEGF-D.

22. (Previously presented) The method according to claim 19, wherein said vascular endothelial growth factor is VEGF-C.

23. (Previously presented) The method according to claim 19, wherein the serine protease is plasmin.

24. (Withdrawn) The method according to claim 15, wherein the composition is administered to said patient by local administration.

25. (Withdrawn) The method according to claim 15, wherein the serine protease is plasmin.